We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens
Product News

Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens

Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens
Product News

Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Immunotope Inc. and Immunovaccine Inc. have announced that the U.S. Patent and Trademark Office has issued an official Notice of Allowance for a new U.S. Patent specific to the DPX-0907 therapeutic cancer vaccine.

The new U.S. patent application titled "Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer" provides additional intellectual property protection in the U.S. for the seven antigens used in Immunovaccine's DPX-0907, a therapeutic cancer vaccine for patients with breast, ovarian or prostate cancers.

"We are delighted that the U.S. Patent and Trademark Office has recognized the novelty of our cancer antigens. The issuance of this patent will enhance the commercial potential of DPX-0907 in the largest market for cancer therapeutics in the world," commented Dr. Ramila Philip, President and CSO of Immunotope Inc.

"This new patent, in addition to our family of patents relating to our DepoVax™ vaccine delivery platform, provides a very strong intellectual property position for DPX-0907 in the U.S." said Dr. Marc Mansour, Vice President of R&D at Immunovaccine Inc.

In July 2009, Immunovaccine obtained exclusive worldwide rights to license the seven antigens from Immunotope. These antigens are believed to be present on the surface of breast, ovarian and prostate cancers and part of critical cancer cell processes. For more information on the seven antigens visit www.imvaccine.com/userfiles/file/7CancerAntigens.pdf

Immunovaccine is completing a Phase I clinical trial for DPX-0907 and preliminary results have shown the vaccine to be well tolerated and safe. Immunovaccine has recently completed enrollment for this trial and will be evaluating additional safety and immune response data that will be available in the second quarter of 2011.

Advertisement